BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
36.85
+0.05 (0.12%)
At close: Feb 21, 2025, 4:00 PM
36.81
-0.04 (-0.11%)
After-hours: Feb 21, 2025, 4:00 PM EST
BridgeBio Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Cash & Equivalents | 681.1 | 375.94 | 376.69 | 393.77 | 356.08 | Upgrade
|
| Short-Term Investments | - | 58.95 | 95.23 | 442.89 | 251.01 | Upgrade
|
| Cash & Short-Term Investments | 681.1 | 434.88 | 471.92 | 836.66 | 607.09 | Upgrade
|
| Cash Growth | 56.62% | -7.85% | -43.59% | 37.81% | 11.19% | Upgrade
|
| Accounts Receivable | 4.72 | 1.75 | 17.08 | 19.75 | - | Upgrade
|
| Receivables | 4.72 | 1.75 | 17.08 | 19.75 | - | Upgrade
|
| Prepaid Expenses | 34.74 | 13.31 | 21.92 | 32.27 | 35.59 | Upgrade
|
| Restricted Cash | 0.13 | 16.65 | 37.93 | 0.18 | 0.14 | Upgrade
|
| Other Current Assets | - | 11 | - | - | - | Upgrade
|
| Total Current Assets | 720.69 | 477.59 | 548.85 | 888.86 | 642.82 | Upgrade
|
| Property, Plant & Equipment | 12.78 | 19.84 | 25.25 | 45.97 | 36.83 | Upgrade
|
| Long-Term Investments | 143.75 | - | - | - | - | Upgrade
|
| Other Intangible Assets | 23.93 | 26.32 | 28.71 | 44.93 | - | Upgrade
|
| Other Long-Term Assets | 18.2 | 22.63 | 20.22 | 33.03 | 23.93 | Upgrade
|
| Total Assets | 919.34 | 546.38 | 623.04 | 1,013 | 703.59 | Upgrade
|
| Accounts Payable | 9.62 | 10.66 | 11.56 | 11.88 | 8.95 | Upgrade
|
| Accrued Expenses | 125.67 | 116.97 | 95.54 | 116.75 | 71.9 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 1.46 | Upgrade
|
| Current Portion of Leases | - | 4.13 | 3.68 | 4.94 | 3.8 | Upgrade
|
| Current Unearned Revenue | - | 6.1 | 8.16 | - | - | Upgrade
|
| Other Current Liabilities | - | 6 | 2.5 | 1.5 | 9.55 | Upgrade
|
| Total Current Liabilities | 135.29 | 143.84 | 121.43 | 135.07 | 95.65 | Upgrade
|
| Long-Term Debt | 1,721 | 1,727 | 1,708 | 1,704 | 475.86 | Upgrade
|
| Long-Term Leases | 9.2 | 8.98 | 12.27 | 17.43 | 14.68 | Upgrade
|
| Long-Term Unearned Revenue | 31.7 | 3.8 | 7.1 | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | - | - | 1.1 | Upgrade
|
| Other Long-Term Liabilities | 479.38 | 5.56 | 19.54 | 22.07 | 8.42 | Upgrade
|
| Total Liabilities | 2,377 | 1,889 | 1,868 | 1,878 | 595.7 | Upgrade
|
| Common Stock | -1,468 | 0.18 | 0.16 | 0.15 | 0.13 | Upgrade
|
| Additional Paid-In Capital | - | 1,481 | 938.7 | 841.53 | 1,021 | Upgrade
|
| Retained Earnings | - | -2,561 | -1,918 | -1,437 | -888.76 | Upgrade
|
| Treasury Stock | - | -275 | -275 | -275 | -75 | Upgrade
|
| Comprehensive Income & Other | - | 0.03 | -0.33 | -0.13 | 0.19 | Upgrade
|
| Total Common Equity | -1,468 | -1,354 | -1,255 | -870.41 | 57.91 | Upgrade
|
| Minority Interest | 10.29 | 11.72 | 9.69 | 4.84 | 49.98 | Upgrade
|
| Shareholders' Equity | -1,458 | -1,343 | -1,245 | -865.58 | 107.89 | Upgrade
|
| Total Liabilities & Equity | 919.34 | 546.38 | 623.04 | 1,013 | 703.59 | Upgrade
|
| Total Debt | 1,731 | 1,740 | 1,724 | 1,726 | 495.79 | Upgrade
|
| Net Cash (Debt) | -1,049 | -1,305 | -1,252 | -889.51 | 111.31 | Upgrade
|
| Net Cash Growth | - | - | - | - | -77.07% | Upgrade
|
| Net Cash Per Share | -5.64 | -8.02 | -8.49 | -6.16 | 0.94 | Upgrade
|
| Filing Date Shares Outstanding | 189.44 | 175.83 | 151.37 | 147.61 | 146.54 | Upgrade
|
| Total Common Shares Outstanding | 189.44 | 175.08 | 150.63 | 147.34 | 122.85 | Upgrade
|
| Working Capital | 585.4 | 333.75 | 427.43 | 753.79 | 547.18 | Upgrade
|
| Book Value Per Share | -7.75 | -7.73 | -8.33 | -5.91 | 0.47 | Upgrade
|
| Tangible Book Value | -1,492 | -1,381 | -1,283 | -915.35 | 57.91 | Upgrade
|
| Tangible Book Value Per Share | -7.88 | -7.89 | -8.52 | -6.21 | 0.47 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.